The fgf-2 gene encodes low molecular weight (LMW, 18 kDa) and high molecular weight (HMW,(22)(23)(24) forms that originate from alternative translation of a single mRNA and exhibit diverse biological functions. HMW fibroblast growth factor-2 (FGF-2) inhibits cell migration and induces cell transformation or growth arrest in a cell type-and dose-dependent fashion. Conversely, LMW FGF-2 upregulates both cell proliferation and migration in most cell types. Although transcriptional and translational regulation of HMW and LMW FGF-2 has been extensively investigated, little is known about posttranslational control of their relative expression. Here we report that thrombin, a key coagulation factor and inflammatory mediator, cleaves HMW FGF-2 into an LMW FGF-2-like form that stimulates endothelial cell migration and proliferation. The effect of thrombin on these cell functions requires HMW FGF-2 cleavage. This post-translational control mechanism adds a novel level of complexity to the regulation of FGF-2, and links the activities of thrombin and FGF-2 in patho-physiological processes in which both molecules are expressed.
Introduction
Basic fibroblast growth factor (FGF-2) is the prototypic member of a growing family of small proteins (Itoh and Ornitz, 2004) . In humans, at least four different molecular weight forms of FGF-2 are generated from alternative translation of a single mRNA transcript. Translation of the 18 kDa form, or low molecular weight (LMW) FGF-2, is initiated from an AUG codon. Translation of the 22, 22.5 and 24 kDa forms, known as high molecular weight (HMW) FGF-2, is initiated from CUG codons upstream of the AUG (Florkiewicz and Sommer, 1989; Prats et al., 1989; Vagner et al., 1995) . The HMW forms of FGF-2 are therefore colinear extensions of 18 kDa FGF-2 (Sorensen et al., 2006; Yu et al., 2007) . Post-translational methylation of arginine residues in the RG-rich N-terminal end controls nuclear accumulation of HMW FGF-2 (Burgess et al., 1991; Pintucci et al., 1996; Klein et al., 2000) . Therefore, HMW FGF-2 forms are predominately nuclear and nucleolar, whereas LMW FGF-2 is mostly cytoplasmic. All FGF-2 forms lack a conventional signal peptide sequence for secretion. However, all of them are released from cells following lethal or sublethal damage (Yu et al., 2007) or by other mechanisms (Mignatti et al., 1991; Piotrowicz et al., 1997; Taverna et al., 2003) . HMW and LMW FGF-2 induces expression of different genes, thus generating unique phenotypes (Quarto et al., 2005) . Overexpression of HMW and LMW FGF-2 promotes cell transformation. However, increased cell migration and changes in integrin pattern are specific to LMW FGF-2 and mediated through receptor tyrosine kinase(s) (Klein et al., 1996) . In contrast, selective expression of HMW forms does not increase cell migration and results in cell transformation by a receptor tyrosine kinaseindependent mechanism(s) (Bikfalvi et al., 1995) .
The relative amount of FGF-2 forms differs among cell types and developmental stages (Yu et al., 2007) . Furthermore, selective expression of HMW FGF-2 is induced by stress conditions such as heat shock and oxidative stress, cytokines and growth factors (Yu et al., 2007) . The different FGF-2 forms have been implicated in various pathological conditions, including vascular remodeling and restenosis, neuronal regeneration after injury and tumor growth. Selective overexpression of HMW FGF-2 correlates with poor prognosis in malignancies such as neural tumors, prostatic cancer, pituitary adenomas and pancreatic cancers (Yu et al., 2007) . Translational regulation through the preferential use of alternative start codons is considered as the major control mechanism for expression of the different FGF-2 forms (Touriol et al., 2003) . However, little is known about potential post-translational control mechanisms.
Thrombin is a key regulator of vascular integrity and homeostasis, acting as a coagulation factor, angiogenic factor, inflammatory mediator, platelet agonist and regulator of vascular cell functions (Mann, 2003) . Generation of thrombin through activation of the tissue factor-dependent coagulation cascade is well described in malignancy (Rickles et al., 2003) . Thrombin has indeed been shown to promote tumor growth and metastasis. This effect has been attributed in part to its angiogenic activity (Even-Ram et al., 1998; Tsopanoglou and Maragoudakis, 1999) and to the effects of chemokines, growth factors and extracellular proteins induced by thrombin (Daniel et al., 1986; Papadimitriou et al., 1997) . Most of thrombin effects have been attributed to activation of specific protease-activated receptors (PARs) and downstream intracellular signaling (Coughlin, 2005) . Here we show that thrombin also induces its mitogenic and pro-migratory effects by cleaving HMW FGF-2 to generate a previously unidentified FGF-2 form containing a short N-terminal extension of LMW FGF-2. This novel FGF-2 form mediates the pro-migratory and proliferative effect of thrombin on endothelial cells.
Results

Thrombin cleaves HMW FGF-2
While investigating vascular responses to vein graft arterialization, we found a dramatic and rapid increase in vein graft-associated thrombin activity (Sharony et al., 2006) . Because this effect was paralleled by an apparent increase in LMW FGF-2 and disappearance of HMW FGF-2 in the vein grafts, we hypothesized that thrombin cleaves HMW FGF-2 into LMW forms in vascular cells. Therefore, we characterized the effect of thrombin on FGF-2 forms in endothelial cell cultures. Addition of thrombin to the culture medium resulted in loss of cell-associated HMW FGF-2 and concomitant accumulation of LMW FGF-2 ( Figure 1a ). This effect occurred within 5 min of thrombin treatment, indicating that it did not result from a translational mechanism. Consistent with this finding, thrombin treatment of murine FGF-2 À/À endothelial cells transiently transfected with human HMW FGF-2 (FGF 365 ) resulted in rapid disappearance of HMW FGF-2 and generation of an FGF-2 form that co-migrated with LMW FGF-2 in polyacrylamide gel electrophoresis (Figure 1a) .
To determine if the generation of LMW FGF-2 by thrombin is dependent on activation of the thrombin receptor, we treated BCE cells with the thrombin receptor agonist peptide (TRAP). As expected (Rauch et al., 2005) , TRAP induced transient activation of extracellular signal-regulated kinase (ERK)-1/2 but did not alter the relative levels of HMW and LMW FGF-2 (Figure 1b) . However, consistent with previous reports (Rauch et al., 2004) , TRAP increased FGF-2 expression at later time points. Conversely, thrombin treatment resulted in loss of HMW FGF-2 and accumulation of LMW FGF-2 (Figure 1b) . These results indicated that the rapid accumulation of LMW FGF-2 induced by thrombin results from proteolytic cleavage of HMW FGF-2 and is independent of thrombin receptor activation. This effect was indeed inhibited by both the serine protease inhibitor Pefabloc and the thrombinspecific inhibitor hirudin (Figure 1c ). We will refer to this cleavage product of FGF-2 as ELF-2 (Eighteen kDa-Like FGF-2) to distinguish it from 18 kDa FGF-2.
To rule out the possibility that thrombin acts on HMW FGF-2 indirectly through a cell-dependent mechanism, we purified HMW FGF-2 by heparin affinity followed by incubation with thrombin at 371C. Thrombin rapidly cleaved purified HMW FGF-2 (Figure 1d) , showing that ELF-2 is directly generated by thrombin and not by signaling events secondary to thrombin interaction with PARs.
Both LMW and HMW FGF-2 are released from cells by a number of mechanisms, among which injury is a major one (Yu et al., 2007) . Therefore, we subjected endothelial cells to sublethal damage by exposure to oxidative stress with 400 mmol l À1 of H 2 O 2 or by transient transfection with HMW FGF-2 complementary DNA (cDNA). Immunoblotting of the cell-conditioned medium under either treatment showed that all forms of FGF-2 were released from the cells, and that thrombin treatment resulted in extracellular proteolysis of HMW FGF-2 (Figure 1e ). These experiments also indicated that ELF-2 is the ultimate C-terminal product of HMW FGF-2 proteolysis by thrombin. Consistent with previous reports (Lobb, 1988) , we also found that thrombin does not cleave 18 kDa FGF-2 (Supplementary Figure 1) .
Identification of thrombin cleavage sites on HMW FGF-2 ELF-2 exhibited a slightly lower electrophoretic mobility than 18 kDa FGF-2 (Figure 1a ), suggesting that the thrombin cleavage site(s) is located upstream of the N-terminal initiator methionine of LMW FGF-2. Comparison of the N-terminal sequence of HMW FGF-2 with known consensus sequences for thrombin cleavage indicated three putative sites ( Figure 2 ). We therefore generated FGF-2 mutants containing alanine (A) substitutions of the arginines (R) at the putative cleavage sites (Figure 2 ; FGF mutÀ7 , FGF mutÀ10 , FGF mutÀ16 and combinations thereof). These mutations were generated in a human HMW FGF-2 cDNA that contains a point mutation in the AUG start codon which prevents translation of 18 kDa FGF-2 (FGF 365 ). Therefore, the LMW FGF-2 detected upon thrombin treatment can only originate from cleavage of HMW FGF-2. FGF-2 À/À endothelial cells transfected with either FGF 365 or mutant cDNAs were treated with thrombin, and FGF-2 expression was analysed by immunoblotting. Single mutations of any one of the three putative cleavage sites did not confer resistance to thrombin cleavage. However, thrombin cleavage of FGF-2 was abolished in double or triple mutants ( Figure 3 ). The double mutant FGF mutÀ10/mutÀ7 was cleaved by thrombin. These results indicated that all three R residues serve as sites for thrombin cleavage, and that mutation of R-16 is necessary but not sufficient to abolish thrombin cleavage.
Cleavage of HMW FGF-2 mediates thrombin stimulation of endothelial cell migration and proliferation
We have previously shown that wound-induced cell migration is strongly impaired in FGF-2 À/À endothelial cells (Pintucci et al., 2002) . Therefore, we analysed the effect of thrombin cleavage of HMW FGF-2 on the migration of FGF-2 À/À endothelial cells stably transfected with either cleavage-permissive or -resistant human HMW FGF-2. For these experiments, we used 1.5 U ml À1 of thrombin, a physiological concentration (Ishibashi et al., 2003) Thrombin promoted migration only in cells that express cleavage-permissive HMW FGF-2, while exogenous 18 kDa FGF-2 had a pro-migratory effect in all the cell transfectants ( Figure 4a ). Thrombin-induced migration was abolished by neutralizing FGF-2 antibody (Figure 4b) , showing that the pro-migratory effect of thrombin is mediated by HMW FGF-2-derived ELF-2.
To characterize the effect of thrombin cleavage of HMW FGF-2 on endothelial cell proliferation, we measured bromodeoxyuridine (BrdU) incorporation in FGF-2 À/À endothelial cells stably transfected with cleavage-permissive or -resistant HMW FGF-2. Thrombin ) for 5 min. 1, control medium; 2; control medium supplemented with human recombinant FGF-2 (10 ng ml À1 ) for 5 min; 3, control medium plus thrombin; 4, H 2 O 2 (400 mM) treatment for 6 h; lane 5, H 2 O 2 (400 mM) treatment for 6 h followed by thrombin treatment. Conditioned media were affinity-concentrated with heparin-Sepharose before immunoblotting with anti-FGF-2 antibody. Each experiment was repeated at least three times with comparable results. LMW, low molecular weight; FGF-2, fibroblast growth factor-2; HMW, high molecular weight; ERK-1/2, extracellular-signal-regulated kinase-1/2; TRAP, thrombin receptor agonist peptide. (Figure 5a ). As observed for cell migration, the effect of thrombin was abolished by neutralizing FGF-2 antibody (Figure 5b) . These results showed that cleavage of HMW FGF-2 mediates thrombin induction of endothelial cell migration and proliferation.
Signaling generated by thrombin through PAR-1 activation controls endothelial cell migration and proliferation (Coughlin, 2005) . Therefore, it is possible that while cleavage of HMW FGF-2 is required for thrombin stimulation of endothelial cell proliferation and migration, ELF-2 may need to synergize with thrombin signaling to stimulate these cell functions. To investigate this possibility, we first characterized the expression profile of PARs in our murine endothelial cell transfectants expressing human HMW FGF-2 (365 cells). et al., 2000) , we found that PAR-1 is expressed in these cells (Supplementary Figure 3) , whereas PAR-3, a receptor with lower affinity for thrombin than PAR-1, is poorly expressed and PAR-4 expression is negligible. Only PAR-2, a receptor specific for multiple trypsin-like serine proteases but not for thrombin, is expressed at comparable levels as PAR-1 in our cells. Transient transfection with PAR-1 small interfering RNA (siRNA) resulted in strong downregulation of PAR-1 expression (Figure 6a ) but did not affect thrombin induction of cell migration and proliferation (Figures 6b and c) although it abolished TRAP-induced ERK-1/2 signaling ( Supplementary Figure 4) . Thus, thrombin cleavage of HMW FGF-2 and generation of ELF-2 are not only required but also sufficient to trigger endothelial cell migration and proliferation without concomitant signaling mediated by PAR-1 activation. À1 of thrombin in the presence of 40 mg ml À1 of either non-immune IgG or anti-FGF-2 antibody. *Pp0.01 (antibody vs non-immune IgG). These experiments were repeated at least three times with comparable results. IgG, immunoglobulin G; FGF, fibroblast growth factor; HMW, high molecular weight; LMW, low molecular weight. À/À cells treated with thrombin in the presence of either 40 mg ml À1 of non-immune IgG or anti-FGF-2 antibody. *Pp0.05 (antibody vs non-immune IgG). These experiments were repeated at least three times with comparable results. FGF, fibroblast growth factor; HMW, high molecular weight; LMW, low molecular weight; IgG, immunoglobulin G; BrdU, bromodeoxyuridine.
Consistent with previous reports (O'Brien
Discussion
The data presented show that thrombin cleaves HMW FGF-2, which inhibits cell migration and proliferation, to generate an LMW FGF-2-like product (ELF-2) that stimulates these cell functions. Thrombin promotes cell proliferation and migration by a mechanism partly mediated by autocrine production of FGF-2 (Herbert et al., 1994; Cucina et al., 2002; Rauch et al., 2004) as a result of transcriptional and translational mechanisms secondary to PAR activation. The thrombin cleavage of HMW FGF-2 we described represents a rapid mechanism of post-translational control of FGF-2 activity independent of PAR activation. This conclusion is supported by our observation that TRAP, a peptide agonist of thrombin receptor, neither decreases HMW nor increases LMW FGF-2 expression. The FGF-2 À/À endothelial cells used in our study express thrombin receptors PAR-1 to -3, in agreement with previous findings in human umbilical vein endothelial cells (O'Brien et al., 2000; Supplementary Figure 3) . We found that suppression of PAR-1 expression by siRNA silencing did not affect thrombin induction of cell migration and proliferation in cells expressing human HMW FGF-2. Furthermore, as TRAP activates PARs without the proteolytic activity of thrombin, its inability to generate ELF-2 shows that the generation of an LMW-like FGF-2 is mediated by the proteolytic activity of thrombin and not by PAR activation. Therefore, our results show that LMW FGF-2 activity can be induced by thrombin by both translation-dependent and -independent mechanisms. HMW FGF-2 inhibits cell migration (Ding et al., 2002) , and induces cell transformation or growth arrest depending on cell type and expression level (Yu et al., 2007) . Our stable HMW FGF-2 transfectants consistently showed decreased proliferation as compared to their FGF-2-null counterpart (data not shown). Thus, cleavage of HMW FGF-2 to ELF-2, a molecule with biological activity similar to that of 18 kDa FGF-2, represents a remarkable mechanism for switching a precursor molecule with inhibitory activity into a proliferative and pro-migratory growth factor (Figure 7) .
Thrombin cleaves tau, an intracellular protein implicated in neurodegenerative disease (Arai et al., 2005) , suggesting that it may cleave intracellular proteins. Conversely, thrombin cleavage of HMW FGF-2 likely occurs at the cell surface and/or in the extracellular environment. In fact, while we cannot rule out the possibility that HMW FGF-2 cleavage observed in cell lysates occurs at the cell surface and is possibly completed during cell lysis, its most relevant cleavage likely occurs in the extracellular environment, where HMW FGF-2 is massively released upon injury (Yu et al., 2007) (Figure 1) . Indeed, both LMW and HMW FGF-2 are exported from the cell through alternative, endoplasmic reticulum-Golgi-independent pathways, and are released upon cell death, wounding or sublethal cell damage (Yu et al., 2007) . We showed that release of all forms of FGF-2 occurs in damaged endothelial cells, for example, under oxidative stress. This finding has physiopathological implications as endothelial damage often occurs concomitantly with thrombin generation in the vascular bed, thus allowing thrombin-HMW FGF-2 interaction in the extracellular environment. It remains to be determined whether other serine proteinases involved in inflammation can also cleave HMW FGF-2 with an effect similar to that of thrombin.
FGF-2 activity is controlled at multiple levels including gene transcription and selective translation of HMW or LMW forms (Sorensen et al., 2006; Yu et al., 2007) . Recently, a 16 kDa form originated by proteolysis of 18 kDa FGF-2 has been described (Malecki et al., 2004) . However, consistent with previous reports (Lobb, 1988) , we found that thrombin does not cleave 18 kDa FGF-2 (Supplementary Figure 1) ; therefore, ELF-2 is the ultimate product of HMW FGF-2 proteolysis by thrombin.
FGF-2, a ubiquitous growth factor, has been implicated in a variety of physiological and pathological processes including tumor growth, bone remodeling, angiogenesis, wound healing and vascular remodeling (Ornitz and Itoh, 2001; Yu et al., 2007) . Thrombin has also been shown to be involved in many of the same processes, notably in cardiovascular and neoplastic conditions. In addition, proteolytic activities including thrombin have been described in areas where HMW FGF-2 expression is particularly elevated, such as in the brain (Claus et al., 2004; Arai et al., 2005) . Therefore, thrombin cleavage of HMW FGF-2 can be involved in a variety of physiopathological settings and represent a mechanism for the control of both FGF-2 and thrombin activities.
Materials and methods
Reagents and antibodies
Human recombinant FGF-2 was purchased from Gibco BRL, Life Technologies, Inc. (Rockville, MD, USA). Anti-human FGF-2 monoclonal antibody (354FI) was a generous gift from Texas Bio-Technologies (Houston, TX, USA). Bovine and human thrombin were purchased from Calbiochem (La Jolla, CA, USA) and Sigma-Aldrich (Saint Louis, MO, USA), respectively. TRAP was from Bachem Bioscience, Inc. (King of Prussia, PA, USA), phospho-ERK-1/2 antibody from Cell Signaling Technologies (Beverly, MA, USA) and ERK-2 antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cells and culture conditions
Media and serum were from Mediatech, Inc. (Herndon, VA, USA). Murine FGF-2 À/À and bovine capillary endothelial cells (BCE; Cell Applications, San Diego, CA, USA) were grown as described (Pintucci et al., 2002) . NIH 3T3 cells expressing human HMW or LMW FGF-2 were a generous gift from Dr Daniel B Rifkin (NYU School of Medicine) and have been described (Bikfalvi et al., 1995) .
Mutation of cleavage sites
Human HMW FGF-2 cDNA with a point mutation in the 365 base pair start codon (a gift from Dr Natalina Quarto, Stanford University, CA, USA) was cloned in pcDNA 3.1( þ ) (FGF 365 Rev ). All mutations were generated by PCR using ThermalAce DNA Polymerase (Invitrogen, Carlsbad, CA, USA), with an annealing temperature of 56 1C, and the sequence for bovine growth hormone polyadenylation signal as the reverse primer: 5 0 -TAGAAGGCACAGTCGAGGCT GAT-3 0 . Arginine to alanine mutations were generated using FGF 365 Rev plasmid as a template and the following forward primers (the mutated codons are boldfaced). 0 -CCCTGCGGGGCCCGGCGCGGATCCCGCAGCCGC-3 0 , template FGF mut-16/-10 Rev . The PCR products were digested with Apa1 (New England Biolabs, Ipswich, MA, USA) and cloned into the Apa1 site of FGF 365 Rev . The plasmids were digested with EcoRI (New England Biolabs) to excise the mutated FGF-2 cDNA, which was cloned back in the correct orientation in both pcDNA 3.1( þ ) and pcDNA 3.1/zeo ( þ ) (Invitrogen). The mutants were characterized by DNA sequencing with Applied Biosystems 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA).
Transfection
FGF-2
À/À endothelial cells at 40% confluency were transfected with 4 mg of human wt or mutant HMW FGF-2 cDNA and 12 ml of Lipofectamine 2000 (Invitrogen). The medium was replaced with fresh a-MEM containing 10% fetal calf serum 6 h after transfection. Figure 7 Effect of thrombin cleavage on human HMW FGF-2 activity. The human fgf-2 gene encodes four major forms of FGF-2 (24, 22.5 and 22 kDa, or HMW FGF-2, and 18 kDa FGF-2, or LMW FGF-2) that originate from a unique mRNA (the start of each form is indicated by a thin arrow). HMW FGF-2 is released from the cell following cell or tissue damage, conditions that also lead to thrombin formation. Thrombin cleaves all HMW FGF-2 forms into an LMW FGF-2-like form (ELF-2) that stimulates cell migration and proliferation. FGF, fibroblast growth factor; HMW, high molecular weight; LMW, low molecular weight.
Immortalization of FGF-2
À/À cells Primary FGF-2 À/À endothelial cells were immortalized by retroviral transduction with human telomerase. The virus was generated in the 293 derivative Phoenix-Eco packaging cell line (a gift from Dr Garry Nolan, Stanford University, and Dr Susan Smith, NYU School of Medicine) as described (Counter et al., 1998) .
Generation of stable transfectants
Immortalized FGF-2 À/À endothelial cells were transfected with Lipofectamine 2000 and human wt (FGF 365 ) or mutant HMW FGF-2 cDNA in pcDNA 3.1/zeo. ( þ ). At 48 h after transfection, the cells were placed in medium containing 2 mg ml À1 of zeocin (Invitrogen). Resistant clones were screened for FGF-2 expression by immunoblotting, and clones with comparable levels of FGF-2 were used in the experiments.
Immunoblotting
Conditioned media were incubated with heparin-Sepharose beads (Bio-Rad Laboratories, Hercules, CA, USA) with gentle rocking at 4 1C for 1 h. After centrifugation at 2000 r.p.m. for 1 min in an Eppendorf centrifuge, reducing sample buffer was added to the beads and loaded onto a sodium dodecylsulfatepolyacrylamide gel for electrophoresis. Conditioned media and cell extracts were analysed by immunoblotting as described (Pintucci et al., 2002) .
Thrombin cleavage of purified HMW FGF-2
Cell extracts were incubated with heparin-Sepharose beads (Bio-Rad Laboratories) with gentle rocking at 4 1C for 1 h. Washed beads were then incubated with 1.5 U ml À1 of thrombin at 37 1C for 15 min, and loaded onto sodium dodecylsulfate--polyacrylamide gel for electrophoresis gels for immunoblotting analysis.
Reverse transcriptase-PCR Total RNA was isolated from FGF-2 À/À cells stably transfected with either FGF 365 or the triple mutant FGF mut-16/mut-10/mut-7 using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). In total, 1 mg of RNA was used for first-strand cDNA synthesis with SuperScript First-Strand Synthesis System for reverse transcriptase-PCR (Invitrogen) followed by PCR amplification of PARs 1-4 as described (Balcaitis et al., 2003) .
Cell migration and proliferation assays Cell migration and proliferation were characterized as described (Pintucci et al., 2002; Ferrari et al., 2006) . siRNA silencing FGF 365 cells at 40% confluency in 6-cm dishes were transfected with 100 pmol of PAR-1 siRNA or scrambled control siRNA (Santa Cruz Biotechnology) using Lipofectamine 2000 (Invitrogen) as described (Ferrari et al., 2006) . Wound assay and BrdU incorporation assay were performed 72 h post transfection as described (Pintucci et al., 2002; Ferrari et al., 2006) . PAR-1 expression was also characterized by reverse transcriptase-PCR 72 h post transfection. Control experiments for TRAP-induced signaling were performed on serum-starved cells incubated with or without TRAP-1 (H-Ser-Phe-Phe-LeuArg-Asn-OH) (100 mM) specific for murine PAR-1 (Bachem Bioscience, Inc) for 15 min. Human thrombin (1.5 U ml
À1
) was alternatively added as a further control for these experiments. Cell lysates were tested for ERK-1/2 signaling as described above.
